New drug shows promise for Hard-to-Treat cancers
NCT ID NCT03401385
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug, DS-1062a, in people with advanced solid tumors like lung and breast cancer that haven't responded to other treatments. It's the first time this drug is being used in humans, so the main goals are to check safety, find the right dose, and see if it helps shrink tumors. About 890 participants will take the drug, and those who benefit can continue until their disease gets worse or side effects become too severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE-RECEPTOR-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Center
Nagoya, Aichi-ken, 464-8681, Japan
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Johns Hopkins Sibley Memorial Hospital
Washington D.C., District of Columbia, 20016, United States
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
-
National Cancer Center Hospital
Chūōku, 104-0045, Japan
-
National Cancer Center Hospital East
Kashiwa, 277-8577, Japan
-
Next Oncology
San Antonio, Texas, 78229, United States
-
START Oncology
San Antonio, Texas, 78229, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37205, United States
-
Showa Medical University Hospital
Shinagawa-Ku, Tokyo, 142-0064, Japan
-
The Cancer Institute Hospital of Japanese Foundation For Cancer Research
Koto-Ku, Tokyo, 135-8550, Japan
-
Tisch Cancer Institute, Icahn School of Medicine
New York, New York, 10029, United States
-
University of California, Los Angeles
Los Angeles, California, 90095, United States
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
-
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322, United States